Liposomal Amphotericin B for Invasive Fungal Disease in Solid Organ Transplant Recipients (LAMB-SOT)
A Real-World Observational Study of the Effectiveness, Safety, and Therapeutic Drug Monitoring of Liposomal Amphotericin B in Solid Organ Transplant Recipients With Invasive Fungal Disease
This real-world observational study aims to evaluate the effectiveness, safety, and therapeutic drug monitoring (TDM) of liposomal amphotericin B (L-AmB) in solid organ transplant recipients with invasive fungal disease (IFD). IFD is a major cause of morbidity and mortality in transplant recipients because of long-term immunosuppressive therapy and increased susceptibility to opportunistic fungal infections.
This is a single-center ambispective cohort study conducted at Sichuan Provincial People's Hospital. The study includes a prospective cohort of solid organ transplant recipients receiving L-AmB therapy and a historical control cohort treated with alternative systemic antifungal regimens. Clinical management and treatment decisions will be determined by treating physicians according to routine clinical practice, and no study-specific intervention will be introduced.
The study will collect information on demographic characteristics, transplant type, immunosuppressive regimens, fungal pathogens, infection sites, antifungal treatment strategies, laboratory findings, and clinical outcomes. Particular attention will be given to renal safety, electrolyte abnormalities, and therapeutic drug monitoring of liposomal amphotericin B. Plasma concentrations of L-AmB, treatment modifications, temporary treatment discontinuation, and concentration-related safety and effectiveness outcomes will be recorded during antifungal therapy.
The primary outcomes are the 28-day clinical response rate and 84-day all-cause mortality. Secondary outcomes include mycological clearance, acute kidney injury, electrolyte abnormalities, breakthrough fungal infection, treatment discontinuation due to adverse events, liposomal amphotericin B plasma concentrations, and the associations between L-AmB exposure and clinical outcomes or treatment-related toxicities.
The study is expected to provide real-world evidence regarding the effectiveness, safety, and pharmacokinetic characteristics of L-AmB in transplant recipients, support optimization of antifungal treatment strategies, and inform individualized dosing and monitoring approaches in this high-risk population.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Lingai Pan, MD
- Telefonnummer: +86 17708130236
- E-Mail: panlingai2004@163.com
Studienorte
-
-
Sichuan
-
Chengdu, Sichuan, China, 610072
- Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital
-
Kontakt:
- Lingai Pan, MD
- Telefonnummer: +86 17708130236
- E-Mail: panlingai2004@163.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Age 18 to 75 years.
- Recipient of a solid organ transplant.
- Diagnosis of invasive fungal disease (IFD) according to EORTC/MSGERC criteria.
- Receiving liposomal amphotericin B therapy as part of routine clinical care.
- Provision of informed consent for prospective participants.
Exclusion Criteria:
- Known hypersensitivity to amphotericin B formulations.
- Severe hepatic dysfunction (ALT or AST >5× upper limit of normal, or total bilirubin >2× upper limit of normal).
- Severe renal dysfunction requiring permanent discontinuation of antifungal therapy at baseline.
- Pregnancy or breastfeeding.
- Participation judged inappropriate by the investigator.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Liposomal Amphotericin B Cohort
Solid organ transplant recipients with invasive fungal disease receiving liposomal amphotericin B therapy.
|
Liposomal amphotericin B administered for treatment of proven, probable, or possible invasive fungal disease in solid organ transplant recipients according to routine clinical practice.
Dose adjustment and treatment duration are determined by treating physicians.
Andere Namen:
|
|
Historical Control Cohort
Historical control patients with invasive fungal disease treated with alternative systemic antifungal regimens.
|
Alternative systemic antifungal agents including azoles, echinocandins, or other standard antifungal therapies administered according to routine clinical practice in historical control patients with invasive fungal disease.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
28-Day Clinical Response Rate
Zeitfenster: Day 28
|
Proportion of participants achieving complete or partial clinical response at Day 28 after initiation of antifungal therapy.
|
Day 28
|
|
84-Day All-Cause Mortality
Zeitfenster: Day 84
|
All-cause mortality occurring within 84 days after initiation of antifungal therapy.
|
Day 84
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Mycological Clearance Rate
Zeitfenster: Day 28
|
Proportion of participants with documented clearance of fungal pathogens.
|
Day 28
|
|
Acute Kidney Injury
Zeitfenster: Baseline through Day 84
|
Occurrence of acute kidney injury during antifungal treatment.
|
Baseline through Day 84
|
|
Electrolyte Abnormalities
Zeitfenster: Baseline through Day 84
|
Occurrence of hypokalemia, hypomagnesemia, or other treatment-related electrolyte disturbances.
|
Baseline through Day 84
|
|
Breakthrough Fungal Infection
Zeitfenster: Baseline through Day 84
|
Occurrence of breakthrough invasive fungal infection during antifungal therapy.
|
Baseline through Day 84
|
|
Antifungal Treatment Discontinuation Due to Adverse Events
Zeitfenster: Baseline through Day 84
|
Permanent discontinuation of antifungal therapy because of treatment-related adverse events.
|
Baseline through Day 84
|
|
Liposomal Amphotericin B Plasma Concentration
Zeitfenster: Baseline through Day 84
|
Plasma concentration of liposomal amphotericin B measured during antifungal therapy.
|
Baseline through Day 84
|
|
Association Between Liposomal Amphotericin B Exposure and Clinical Response
Zeitfenster: Baseline through Day 84
|
Relationship between liposomal amphotericin B plasma concentration and clinical response.
|
Baseline through Day 84
|
|
Association Between Liposomal Amphotericin B Exposure and Adverse Events
Zeitfenster: Baseline through Day 84
|
Relationship between liposomal amphotericin B plasma concentration and treatment-related adverse events, including nephrotoxicity and electrolyte abnormalities.
|
Baseline through Day 84
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Lingai Pan, MD, Sichuan Provincial People's Hospital
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- KC2025-JX-0390WLH-06 (Andere Zuschuss-/Finanzierungsnummer: Beijing Science and Technology Innovation Medical Development Foundation)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .